Abstract：
Immune checkpoint blockade (ICB) therapy has revolutionized cancer treatment but has shown limited efficacy in gynecologic cancers. VISTA (V-domain Ig suppressor of T-cell activation), a member of the B7 family, is emerging as another checkpoint that regulates the anti-tumor immune responses within the tumor microenvironment. This paper reviews the structure, expression, and mechanism of action of VISTA. Furthermore, it highlights recent advances in VISTA-blocking therapies and their potential in improving outcomes for patients with gynecologic cancers. By understanding the role of VISTA in mediating the immune evasion of gynecologic tumors, we can develop more effective combinatory treatment strategies that could overcome resistance to current ICB therapies.
摘要：
免疫检查点阻断（ICB）疗法彻底改变了癌症治疗，但在妇科癌症中显示出有限的疗效。VISTA（T细胞激活的V域Ig抑制因子），B7家族的一员,正在成为另一个调节肿瘤微环境中抗肿瘤免疫反应的检查点。本文回顾了这一结构，表达式,和VISTA的作用机制。此外，它重点介绍了VISTA阻断疗法的最新进展及其在改善妇科癌症患者预后方面的潜力.通过了解VISTA在介导妇科肿瘤免疫逃避中的作用，我们可以开发更有效的联合治疗策略,以克服对当前ICB疗法的耐药性.
